- Verified Reactivity
- Human
- Reported Reactivity
- Cynomolgus, Cow
- Antibody Type
- Monoclonal
- Host Species
- Mouse
- Immunogen
- MOLM-1 megakaryocytic cell line
- Formulation
- Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
- Preparation
- The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
- Concentration
- Lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
- Storage & Handling
- The CD117 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
- Application
-
FC - Quality tested
SB - Reported in the literature, not verified in house
- Recommended Usage
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood.
- Excitation Laser
- Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
- Application Notes
The 104D2 antibody does not block binding of c-Kit ligand. Additional reported applications (for the relevant formats) include: immunoprecipitation1, immunofluorescence microscopy1, and spatial biology (IBEX)4,5.
- Additional Product Notes
Iterative Bleaching Extended multi-pleXity (IBEX) is a fluorescent imaging technique capable of highly-multiplexed spatial analysis. The method relies on cyclical bleaching of panels of fluorescent antibodies in order to image and analyze many markers over multiple cycles of staining, imaging, and, bleaching. It is a community-developed open-access method developed by the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).
- Application References
(PubMed link indicates BioLegend citation) -
- Broudy VC, et al. 1999. Blood 94:1979. (IF, IP)
- Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
- Nagano M, et al. 2007. Blood 110:151. (FC) PubMed
- Radtke?AJ,?et al.?2020.?Proc Natl Acad Sci U S A.?117:33455-65. (SB)?PubMed
- Radtke?AJ,?et al.?2022.?Nat Protoc.?17:378-401. (SB)?PubMed
- Product Citations
-
- Sun J, et al. 2008. J Biol Chem. 283:27444. PubMed
- Sun J, et al. 2018. Oncogenesis. 7:48. PubMed
- Zhao Y, et al. 2016. Cell Rep. 16:2003-2016. PubMed
- Sun J, et al. 2009. J Biol Chem. 284:11039. PubMed
- Niwa A, et al. 2011. PLoS One. 6:e22261. PubMed
- Cho K, et al. 2017. Biochem Biophys Res Commun. 10.1016/j.bbrc.2017.04.141. PubMed
- Cruse G, et al. 2015. Mol Biol Cell. 26:1711. PubMed
- Taguchi A, et al. 2017. Cell Stem Cell. 21:730. PubMed
- Shen C, et al. 2021. Front Immunol. 12:680055. PubMed
- Lecluze E, et al. 2020. Hum Reprod. 35:1099. PubMed
- Zhang J, et al. 2019. Dev Cell. 48:329. PubMed
- Schielke L, et al. 2022. Front Immunol. 13:916701. PubMed
- Fang F, et al. 2021. Cell Rep. 37:109981. PubMed
- Suzuki S, et al. 2021. STAR Protocols. 2(3):100683. PubMed
- Zeng Z, et al. 2021. Nat Commun. 12:3641. PubMed
- Smith-Díaz CC, et al. 2021. Front Oncol. 11:709543. PubMed
- López-Sanz C, et al. 2022. STAR Protoc. 3:101755. PubMed
- Bender R, et al. 2016. PLoS Pathog. 12: 1005641. PubMed
- Zhang Y et al. 2018. Cell stem cell. 23(4):516-529 . PubMed
- Pan C, et al. 2019. Int J Mol Med. 44:1629. PubMed
- Mpakou V, et al. 2021. Exp Ther Med. 1.010416667. PubMed
- Samuel RM, et al. 2020. Cell Stem Cell. 27:876. PubMed
- Bennstein SB, et al. 2020. eLife. 9:e55232.. PubMed
- Wang G, et al. 2018. Int J Mol Med. 41:791. PubMed
- RRID
- AB_314982 (BioLegend Cat. No. 313203) AB_314983 (BioLegend Cat. No. 313204)
